AIDSWEEKLY Plus; Monday, May 24, 2004
Staff Medical Writers

Immunovirological "outcomes and toxicities of HAART regimens, including Lopinavir (LPV)/ritonavir (r) and indinavir (IDV)/r," were compared in antiretroviral naive HIV-1 patients. Fifty-five and 52 patients, respectively, were selected to start LPV/r or IDV/r as first-line HAART, according to research in Italy.

"Immunovirological and metabolic parameters were recorded at baseline and every 3 months as were side effects, AIDS-defining events and deaths. Demographic characteristics and NRTIs included in the regimens were comparable," wrote M. Bongiovanni and colleagues.

"Both groups reached undetectable HIV-RNA plasma viremia" by the third month, which was maintained during follow-up. However, patients receiving IDV/r were less likely "to obtain virological success (RH: 0.46). Patients receiving IDV/r showed a greater increase of total cholesterol (P = 0.01). Three patients on LPV/r and 21 on IDV/r discontinued the drug for toxicity, leading to an 8.40 higher risk of discontinuation in the latter group," M. Bongiovanni and colleagues reported.

Results indicate that IDV/r is "less effective and more toxic than LPV/RTV as first-line HAART," concluded the investigators.

Bongiovanni and colleagues published the results of their research in Antiviral Research (Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res. 2004 Apr;62(1):53-6.

For additional information, contact M. Bongiovanni, University Milan, L Sacco Hospital Vialba, Institute Infection Diseases & Trop Med, Via GB Grassi 74, I-20157 Milan, Italy.

The publisher of the journal Antiviral Research can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.

The information in this article comes under the major subject areas of AIDS and HIV, Antiretroviral, Pharmaceutical & Drug Development and Toxicity.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Bongiovanni M, Bini T, Chiesa E, et al., "Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects", Antiviral Res. 2004 Apr;62(1):53-6

PubMED Related articles Search

040524
AW0405211

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.